Skip to content

Lifestyle Changes and Glycemic Control in T1D

Lifestyle Changes and Glycemic Control in Type 1 Diabetes Mellitus: A Factorial Design Approach

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03864991
Acronym
LSHBA1C
Enrollment
120
Registered
2019-03-06
Start date
2018-10-29
Completion date
2020-05-31
Last updated
2019-03-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Behavioral Changes, Life Style, Self-Management, Type1 Diabetes Mellitus

Keywords

Log book, Step count, Diet, Physical activity, HbA1c, Blood sugar

Brief summary

Pakistani studies report non-adherence to self-management by type 1 diabetes (T1D) patients, and episodes of hypoglycemia and ketoacidosis as acute complications. Self-management guidelines include maintenance of logbooks for blood glucose, physical activity, and dietary intake, that affect glycated hemoglobin (HbA1C) and acute complications. The proposed study will evaluate whether mobile messaging for maintaining log books for blood glucose or e-device use for step count will modify HbA1c levels to be examined at three and six months after enrollment. In addition, episodes of acute complications and blood glucose variability will be correlated with daily log book maintenance and step counts.

Detailed description

Type 1 diabetes (T1D) occurs due to destruction of insulin producing beta cells in pancreas. T1D usually occurs in children and young individuals, and requires continuous blood glucose monitoring for adjustment of insulin dosage on a daily basis. Incidence of T1D has been increasing over the past three decades. Hyperglycemia and ketoacidosis episodes are common adverse effects due to irregular monitoring of daily blood glucose. It is a big challenge in developed as well as developing countries to live with T1D due to less optimal use of timely entry in logbook for self-monitoring of blood glucose (SMBG). Current guidelines recommend SMBG use in all patients with diabetes. According to a study, increased daily frequency of SMBG was significantly associated with lower glycated hemoglobin (HbA1C) along with added benefits of fewer acute complications among children and adolescents. Available literature from Pakistan highlights non-adherence of T1D patients to recommended dietary advice (58.5%), physical activity (42.3%) and prescribed insulin regimen (88.1%). Use of mobile applications has been shown to increase the medication adherence and use of self-blood glucose testing. Increased daily step count by T1D patients helped to reduce the risk of cardiovascular events. A wearable e-device accompanied with an application (Fitbit App) tracks step count by recording data in mobile application. HbA1C levels acts as an indicator for the glycemic control and correlates with complications. However, HbA1C cannot determine the daily variability of blood glucose, thus SMBG can help predict the average daily risk reduction in T1D complications. The proposed study will address the adherence to standard protocols for maintaining home based records by patients and caregivers and insulin therapy, optimizing the quarterly HbA1C levels.

Interventions

DEVICEe-device for step count (fit-bit)

Patients in this group will receive fitbit device to count their daily steps and record it into their log books.

BEHAVIORALe-messages for log book

Patients in this group will receive e-messages to maintain their log books as per instruction for blood sugar levels and send back weekly through snap shot.

BEHAVIORALe-messages for log book & fit-bit

Patient in this group will receive e-messages to maintain their log books for blood sugar levels as well as use fitbit device and maintain their log book for daily step count and send back weekly through snap shot.

Sponsors

Aga Khan University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
OTHER
Masking
NONE

Intervention model description

A factorial design approach will be taken to study the lifestyle change for self-management of T1D. A randomized controlled method will enroll patients in four groups. All groups will be working with a standard log book for documenting blood sugar and routine care as advise by doctors, nurses, and nutritionists. First group will be entirely of routine care follow up, second group will receive additional e-device for step count (fitbit), third group will receive routine care and e-messages as reminders to maintain a daily log book, and fourth group will be receiving e-device for step count (fitbit) and e-messages for maintain blood glucose and step count log book in addition to routine care. All four groups will be followed up for a period of six months. Log book data will be obtained at a monthly interval and HbA1c as a main outcome will be measured three times, at baseline, at three and six months.

Eligibility

Sex/Gender
ALL
Age
15 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Patient diagnosed with T1D \> 6 months * Patient's age ≥ 15 years * Patient or any one of the family member like father, mother or sibling using smart phone. * Patient or any one of the family member know how to use (receive calls or read text message) a smart phone.

Exclusion criteria

* Patient on insulin pump * Pregnant females, * Patient with neurodevelopmental delay or thalassemia * Patient currently using any kind of authentic e-device for step count or physical activity.

Design outcomes

Primary

MeasureTime frameDescription
Changes in HbA1cEach participant will be in the study for the period of six monthsBlood HbA1c levels will be measured at baseline, three and six months. It will be taken on ratio scale measured in mmol/mol

Secondary

MeasureTime frameDescription
Episodes of acute complicationsEach participant will be in the study for the period of six monthsHyperglycemia \>450 mg/dl or Hi on glucometer, Ketoacidosis per hospital diagnosed, Hypoglycemia \<60 mg/dl or low on glucometer three times a day.

Countries

Pakistan

Contacts

Primary ContactAmna R Siddiqui, Phd
rehana.siddiqui@aku.edu00922134864818
Backup ContactSobiya Q Sawani, MSc
sobiya.sawani@aku.edu00922134864954

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 27, 2026